+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

No survival benefit with adjuvant chemotherapy in nonserous stage IB grade 2 epithelial ovarian cancer



No survival benefit with adjuvant chemotherapy in nonserous stage IB grade 2 epithelial ovarian cancer



Gynecologic Oncology 141: 53-54




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 064886110

Download citation: RISBibTeXText

DOI: 10.1016/j.ygyno.2016.04.161


Related references

Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?. International Journal of Gynecological Cancer 20(7): 1125-1131, 2011

Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. Gynecologic Oncology. 46(3): 357-360, 1992

The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer. Gynecologic Oncology 2019, 2019

Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy. Journal of Obstetrics and Gynaecology Research 44(7): 1284-1293, 2018

Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival. Obstetrics and Gynecology 127(5): 837-847, 2017

Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer. Journal of Obstetrics and Gynaecology 37(8): 1070-1075, 2017

Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy?. Bjog 117(12): 1459-1467, 2010

Surgical Stage I high-grade ovarian cancer: is adjuvant chemotherapy warranted?. European Journal of Gynaecological Oncology 36(6): 633-636, 2016

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer. Plos One 12(9): E0183754, 2017

Survival benefit of adjuvant chemotherapy for patients with poorly differentiated stage IIA colon cancer. Journal of Cancer 10(5): 1209-1215, 2019

Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer. Journal of the American Geriatrics Society 57(8): 1403-1410, 2009

Novel directions in adjuvant chemotherapy for early stage epithelial ovarian cancer. Asian Pacific Journal of Cancer Prevention 16(10): 4157-4160, 2016

Analysis of adjuvant chemotherapy in patients with Stage-III epithelial ovarian cancer. Zhongguo Zhongliu Linchuang 31(3): 141-143, Feb 15, 2004

Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. European Journal of Surgical Oncology 44(6): 760-765, 2018

Adjuvant chemotherapy beneficial for select early-stage, low-grade serous ovarian cancer patients. Gynecologic Oncology 141: 187-188, 2016